* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for QUIA PHARMA AB's PEG Ratio or its related term are showing as below:
FRA:99B0's PEG Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 2.02 * Ranked among companies with meaningful PEG Ratio only.
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
QUIA PHARMA AB (FRA:99B0) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
QUIA PHARMA AB PEG Ratio Related Terms
QUIA PHARMA AB PEG Ratio Historical Data
* Premium members only.
The historical data trend for QUIA PHARMA AB's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:99B0 vs VRTX, REGN, ALNY: PEG Ratio Comparison
For the Biotechnology subindustry, QUIA PHARMA AB's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
QUIA PHARMA AB PEG Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, QUIA PHARMA AB's PEG Ratio distribution charts can be found below:
* The bar in red indicates where QUIA PHARMA AB's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
QUIA PHARMA AB (FRA:99B0) has a PEG Ratio of 0.00 as of Jul. 07, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on QUIA PHARMA AB and its competitors.
Is QUIA PHARMA AB's PEG Ratio too high?
QUIA PHARMA AB's current PEG Ratio is 0.00.
How does QUIA PHARMA AB's PEG Ratio compare to VRTX and REGN?
QUIA PHARMA AB's PEG Ratio of 0.00 can be compared against companies in the Biotechnology industry. The industry median PEG Ratio is 2.02. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Biotechnology company?
The median PEG Ratio among Biotechnology companies is 2.02, based on 94 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on QUIA PHARMA AB and its competitors. For the Biotechnology industry, the median PEG Ratio is 2.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. QUIA PHARMA AB's current PEG Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is QUIA PHARMA AB stock overvalued right now?
QUIA PHARMA AB (FRA:99B0) has a current PEG Ratio of 0.00. The current PEG Ratio is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For QUIA PHARMA AB (FRA:99B0), the current PEG Ratio is 0.00 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
QUIA PHARMA AB is a development company for pharmaceuticals based on a patented drug delivery platform, Uni-Qleaver. The company develops improved and patentable forms of drugs under development or already approved by pharmaceutical authorities. These refined and enhanced forms of medicine are based on the Company's exceptional and patented technology platform. In addition to this, the Company offers multinational sales of omega-3, astaxin and collagen through Amazon.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:99B0 has been successfully added to your 